OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Metrics to compare | OSTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOSTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.2x | −3.1x | −0.5x | |
PEG Ratio | −0.10 | −0.06 | 0.00 | |
Price/Book | −16.5x | 1.3x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.3x | |
Upside (Analyst Target) | - | 203.4% | 40.1% | |
Fair Value Upside | Unlock | −3.0% | 5.1% | Unlock |